佐力药业(300181) - 2024 Q4 - 年度业绩

Financial Performance - Total revenue for 2024 reached CNY 2,579,748,294.85, a year-on-year increase of 32.81%[5] - Operating profit for the period was CNY 604,416,890.81, reflecting a growth of 34.70% compared to the previous year[5] - Net profit attributable to shareholders was CNY 504,677,015.63, up 31.79% from the same period last year[5] - The company’s basic earnings per share rose to CNY 0.72, a 30.91% increase compared to the previous year[5] Asset and Equity Growth - Total assets at the end of the reporting period amounted to CNY 3,999,238,077.12, an increase of 10.26% from the beginning of the period[5] - The company's equity attributable to shareholders increased to CNY 2,772,453,313.70, a growth of 1.60%[5] Product Revenue Growth - The sales revenue of the core product Wuling capsules grew by 17.14%, with sales volume and revenue increasing by 22.62% and 15.96% respectively[7] - The revenue from traditional Chinese medicine pieces increased by 45.82% year-on-year[7] - The revenue from Chinese medicine formula granules surged by 145.34% due to increased regulatory approvals[7] Profitability Improvement - The company’s expense ratio decreased due to the scale effect of sales growth, leading to improved profitability[8]